{"public_id":"cl_737d4868fe5c28cc67d78c6cc79677d4","status":"active","superseded_by_public_id":null,"corpus_id":30901307,"text":"In hyperlipidemic patients, 2 g/day Kelussia powder plus 40 mg/day lovastatin did not produce significant changes in fasting blood glucose or lipid profile compared with lovastatin alone over 14 and 30 days.","confidence":0.96,"paper":{"corpus_id":30901307,"title":"Kelussia odoratissima Mozaffarian and dyslipidemia","url":"https://sah.borca.ai/papers/30901307"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.96,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0a12f708e232dd2068051b7dc5bbeb63","name":"hyperlipidemic patients","description":"Patients with elevated blood lipids included in the human study described in the abstract.","types":["patient group"],"url":"https://sah.borca.ai/concepts/co_0a12f708e232dd2068051b7dc5bbeb63"},{"public_id":"co_451c4eba525f89c05a3e46137de7c14e","name":"lovastatin","description":"A statin drug used as the comparator treatment for lowering lipids.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_451c4eba525f89c05a3e46137de7c14e"},{"public_id":"co_a402d4faa347171d972d8daa436ab8e2","name":"Kelussia powder","description":"Powdered Kelussia odoratissima administered orally in the human comparison described in the abstract.","types":["supplement"],"url":"https://sah.borca.ai/concepts/co_a402d4faa347171d972d8daa436ab8e2"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_737d4868fe5c28cc67d78c6cc79677d4"}